Elgan Pharma
Ness Ziona, Israel· Est.
Israeli biotech developing non‑invasive, organ‑targeted therapies for preterm infants with unmet clinical needs.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Israeli biotech developing non‑invasive, organ‑targeted therapies for preterm infants with unmet clinical needs.
NeonatologyGastroenterologyOphthalmology
Technology Platform
Locally delivered small‑molecule/peptide agents that accelerate organ maturation and mitigate inflammation and oxidative stress in preterm infants.
Opportunities
First‑in‑class therapies for neonatal GI dysfunction and ROP could capture a sizable share of NICU spend and address a critical unmet medical need.
Risk Factors
Clinical trial outcomes, regulatory approval pathways, and limited commercial experience in neonatal markets pose significant risks.
Competitive Landscape
Few companies target neonatal organ maturation; Elgan’s local delivery approach differentiates it from existing supportive care and anti‑VEGF treatments for ROP.